Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
10 drugs in development
By Therapeutic Area
top 1
R&D Momentum
76/100
Pipeline Velocity
45/100
Trial Completion Rate
68/100
Pipeline Concentration
100/100
Pipeline Freshness
16/100
Strategic Signals
Activity
Last 14 days
A Phase II Open Label, Single Arm Study to Evaluate the Efficacy of Pembrolizumab for Leukoplakia
Phase 2 Study of High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for Intermediate and High Risk Localized Prostate Adenocarcinoma (HYDRA)
Functional Radiosurgery for Easing or Eliminating Debilitating Oncologic Morbidity (FREEDOM)
Improving Screening Tools to Better Predict High-Grade Anal Dysplasia for MSM
Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy
UCLA L-11: A Phase II Trial of Ivonescimab for Previously Treated Thymic Carcinoma
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
PET Imaging Study of 68Ga-FAPI-46 Biodistribution in Cancer Patients
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)